# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:BAX) with a Neutral and lowers the price target from $44 to $38.
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite hol...
Clinolipid provides calories and essential fatty acids for parenteral nutritionExpanded indication demonstrates Baxter's co...
TD Cowen analyst Joshua Jennings downgrades Baxter Intl (NYSE:BAX) from Buy to Hold and announces $40 price target.
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a repo...